CO5650164A2 - Hetrociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6 - Google Patents

Hetrociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6

Info

Publication number
CO5650164A2
CO5650164A2 CO05079298A CO05079298A CO5650164A2 CO 5650164 A2 CO5650164 A2 CO 5650164A2 CO 05079298 A CO05079298 A CO 05079298A CO 05079298 A CO05079298 A CO 05079298A CO 5650164 A2 CO5650164 A2 CO 5650164A2
Authority
CO
Colombia
Prior art keywords
alkyl
optionally substituted
cycloalkyl
group
aryl
Prior art date
Application number
CO05079298A
Other languages
English (en)
Inventor
Ronald Charles Bernotas
Yinfa Yan
Albert J Robichaud
Kevin Guangcheng Liu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CO5650164A2 publication Critical patent/CO5650164A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

1.- Compuesto de fórmula I caracterizado porque A es C, CR8 o N;R1 es H, halógeno, CN, COR9, OCO2R10, CO2R11, CONR12R13, SOxR14, NR15R16, OR17 o un grupo alquilo C1-C6, cicloalquilo C3-C7, arilo o heteroarilo cada uno opcionalmente sustituido;R2 es un grupo alquilo C1-6, cicloalquilo C3-C7, arilo o heteroarilo opcionalmente sustituido o un sistema de anillo bicíclico o tricíclico de 8 a 13 elementos opcionalmente sustituido que tiene un átomo N en el puente principal y opcionalmente contiene 1, 2 ó 3 heteroátomos adicionales seleccionados de N, O ó S;R3 es H o un grupo alquilo C1-C6, cicloalquilo C3-C7, arilo o heteroarilo cada uno opcionalmente sustituido;R4 es H o un grupo alquilo C1-C4 o cicloalquilo C3-C7 cada uno opcionalmente sustituido;R5, R6 y R7 son cada uno independientemente H o un grupo alquilo C1-C6 o cicloalquilo C3-C7 cada uno opcionalmente sustituido;m y p son cada uno independientemente un número entero de 1, 2 ó 3;n es un número entero de 1 ó 2;R8 es H, OH o un grupo alcoxi C1-C6 opcionalmente sustituido;R9, R10, R11 y R17 son cada uno independientemente H o un grupo alquilo C1-C6, alquenilo C2-C6, alquinilo C2-C6, cicloalquilo C3-C6, cicloheteroalquilo, arilo o heteroarilo cada uno opcionalmente sustituido;R12, R13, R15 y R16 son cada uno independientemente H o un grupo alquilo C1-C4 opcionalmente sustituido ó R12 y R13 ó R15 y R16 pueden ser tomados junto con el átomo al cual están unidos para formar un anillo de 5 a 7 elementos que opcionalmente contienen otro heteroátomo seleccionado de O, NR18 o SOx;R14 es un grupo alquilo C1-C6, alquenilo C2-C6, alquinilo C2-C6, cicloalquilo C3-C6, cicloheteroalquilo, arilo o heteroarilo cada uno opcionalmente sustituido;R18 es H o un grupo alquilo C1-C6, alquenilo C2-C6, alquinilo C2-C6, cicloalquilo C3-C7, cicloheteroalquilo, arilo o heteroarilo cada uno opcionalmente sustituido;X es 0 ó un número entero de 1 ó 2; y - - - - representa un enlace sencillo o un enlace doble; o los estereoisómeros de los mismos o las sales de los mismos farmacéuticamente aceptables.
CO05079298A 2003-02-14 2005-08-10 Hetrociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6 CO5650164A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44761303P 2003-02-14 2003-02-14

Publications (1)

Publication Number Publication Date
CO5650164A2 true CO5650164A2 (es) 2006-06-30

Family

ID=32908471

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05079298A CO5650164A2 (es) 2003-02-14 2005-08-10 Hetrociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6

Country Status (21)

Country Link
US (3) US7238696B2 (es)
EP (1) EP1592683A2 (es)
JP (1) JP2006518385A (es)
KR (1) KR20050101551A (es)
CN (1) CN100422171C (es)
AR (1) AR043181A1 (es)
AU (1) AU2004213374A1 (es)
BR (1) BRPI0407253A (es)
CA (1) CA2515570A1 (es)
CO (1) CO5650164A2 (es)
CR (1) CR7930A (es)
EC (1) ECSP055964A (es)
MX (1) MXPA05008438A (es)
NO (1) NO20053792L (es)
NZ (1) NZ541699A (es)
PL (1) PL378120A1 (es)
RU (1) RU2347780C2 (es)
TW (1) TW200505904A (es)
UA (1) UA80184C2 (es)
WO (1) WO2004074243A2 (es)
ZA (1) ZA200506416B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1293073C (zh) * 2001-04-20 2007-01-03 惠氏公司 作为5－羟色胺－6配体的杂环基烷氧基－、－烷硫基－和－烷基氨基吲哚衍生物
BR0209056A (pt) * 2001-04-20 2004-08-10 Wyeth Corp Derivados de heterociclilóxi-, -tióxi- e -aminobenzazol como ligantes de 5-hidroxitriptamina-6
RS20060035A (en) 2003-07-22 2008-08-07 Arena Pharmaceuticals Inc., Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
AU2006280091A1 (en) 2005-08-15 2007-02-22 Wyeth Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
CA2619309A1 (en) * 2005-08-15 2007-03-22 Wyeth Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
MX2008009022A (es) * 2006-01-13 2008-09-24 Wyeth Corp 1h-indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina.
PE20071143A1 (es) * 2006-01-13 2008-01-20 Wyeth Corp Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6
JP5255559B2 (ja) * 2006-03-31 2013-08-07 アボット・ラボラトリーズ インダゾール化合物
MX2008012824A (es) * 2006-04-05 2008-10-15 Wyeth Corp Derivados de sulfonil-3-heterociclilindazol como ligandos de 5-hidroxitriptamina-6.
WO2007120596A1 (en) * 2006-04-12 2007-10-25 Wyeth DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
PT2040755E (pt) * 2006-06-23 2011-07-08 Esteve Labor Dr Combinação de um inibidor de colinesterase e um composto com afinidade para o receptor 5-ht6
EP2158195A1 (en) 2007-05-15 2010-03-03 Wyeth LLC 5- (aminoazacyclyl) -3-sulfonyl-lh- indazoles as 5-hydroxytryptamine- 6 ligands for the treatment of cns disorders
US20090012308A1 (en) * 2007-06-13 2009-01-08 Wyeth Process for the manufacture of benzylsulfonylarenes
WO2009074607A1 (en) 2007-12-12 2009-06-18 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2009155399A1 (en) * 2008-06-20 2009-12-23 Wyeth 1-substituted-3-(naphthalen-1-ylsulfonyl)-5-(piperazin-1-yl)-1h-indazole compounds as 5-hydroxytryptamine-6 ligands
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
US8518933B2 (en) * 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
ES2568262T3 (es) * 2009-04-23 2016-04-28 Abbvie Inc. Moduladores de receptores de 5-HT y sus métodos de uso
CN105541693B (zh) 2014-07-08 2018-10-16 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
AU2015341913B2 (en) 2014-11-03 2020-07-16 Iomet Pharma Ltd Pharmaceutical compound
CN104693186B (zh) * 2014-12-31 2017-12-22 青岛黄海制药有限责任公司 一种吲哚衍生物中c‑f键生成c‑n键合成西泮类药物的方法
CN109562085A (zh) 2015-06-12 2019-04-02 阿速万科学有限责任公司 用于预防和治疗rem睡眠行为障碍的二芳基和芳基杂芳基脲衍生物
AU2016291673A1 (en) 2015-07-15 2018-01-25 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
WO2021262587A1 (en) 2020-06-22 2021-12-30 Corcept Therapeutics Incorporated Quaternary indazole glucocorticoid receptor antagonists
WO2023122600A1 (en) * 2021-12-21 2023-06-29 Corcept Therapeutics Incorporated Piperazine indazole glucocorticoid receptor antagonists

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR008245A1 (es) * 1996-06-21 1999-12-29 Glaxo Group Ltd Derivados de acido acetico, uso de los mismos en la fabricacion de un agente terapeutico y proceso para preparar dichos derivados
EA200000488A1 (ru) 1997-11-04 2000-10-30 Пфайзер Продактс Инк. Замена катехина на биоизостеру индазола в терапевтически активных соединениях
EP1343756A2 (en) 2000-11-02 2003-09-17 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
DK1355904T3 (da) 2000-12-22 2007-10-15 Wyeth Corp Heterocyclindazol- og -azaindazolforbindelser som 5-hydroxytryptamin-6-ligander
CN1492863A (zh) 2000-12-22 2004-04-28 作为5-羟色胺-6配基的杂环基烷基-吲哚或氮杂吲哚化合物
TW593278B (en) 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
BR0209056A (pt) * 2001-04-20 2004-08-10 Wyeth Corp Derivados de heterociclilóxi-, -tióxi- e -aminobenzazol como ligantes de 5-hidroxitriptamina-6
CN1293073C (zh) 2001-04-20 2007-01-03 惠氏公司 作为5－羟色胺－6配体的杂环基烷氧基－、－烷硫基－和－烷基氨基吲哚衍生物
WO2002100833A1 (fr) 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Inhibiteurs de rho kinase
EP1414442A1 (en) 2001-08-07 2004-05-06 Smithkline Beecham Plc 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
US20050113283A1 (en) 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
DE60309852T2 (de) 2002-03-27 2007-06-06 Glaxo Group Ltd., Greenford Chinolin- und aza-indolderivate und deren verwendung als 5-ht6 liganden
PL209872B1 (pl) 2002-03-27 2011-10-31 Glaxo Group Ltd Pochodna chinolinowa, sposób jej wytwarzania i jej zastosowanie oraz zawierająca ją farmaceutyczna kompozycja
TW200400177A (en) 2002-06-04 2004-01-01 Wyeth Corp 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands
JP4754821B2 (ja) 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物
TW200401641A (en) 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
TW200403243A (en) 2002-07-18 2004-03-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
CA2515571A1 (en) 2003-02-14 2004-09-02 Wyeth Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
DE102004046356A1 (de) * 2004-09-24 2006-03-30 Clariant Gmbh Verfahren zur Herstellung von Alk(en)ylphosphorsäureestersalzen

Also Published As

Publication number Publication date
KR20050101551A (ko) 2005-10-24
AR043181A1 (es) 2005-07-20
CA2515570A1 (en) 2004-09-02
WO2004074243A2 (en) 2004-09-02
ZA200506416B (en) 2007-02-28
NZ541699A (en) 2009-01-31
RU2347780C2 (ru) 2009-02-27
NO20053792L (no) 2005-08-10
CR7930A (es) 2006-02-07
PL378120A1 (pl) 2006-03-06
US20070232618A1 (en) 2007-10-04
EP1592683A2 (en) 2005-11-09
US20040167122A1 (en) 2004-08-26
US20090253711A1 (en) 2009-10-08
WO2004074243A3 (en) 2004-12-02
US7238696B2 (en) 2007-07-03
AU2004213374A1 (en) 2004-09-02
CN1771244A (zh) 2006-05-10
TW200505904A (en) 2005-02-16
ECSP055964A (es) 2006-01-16
BRPI0407253A (pt) 2006-01-31
UA80184C2 (en) 2007-08-27
JP2006518385A (ja) 2006-08-10
RU2005128556A (ru) 2006-01-27
CN100422171C (zh) 2008-10-01
US7560470B2 (en) 2009-07-14
MXPA05008438A (es) 2005-10-19

Similar Documents

Publication Publication Date Title
CO5650164A2 (es) Hetrociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
AR040566A1 (es) Derivados de 1-heterociclilalquil 3- sulfonilazaindol o azaindazol como ligandos de 5 hidroxitriptamina-6
AR040567A1 (es) Derivados de 1- heterociclilalquil 3- sulfonilindol o -indazol como ligandos de 5- hidroxitriptamina -6
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR043180A1 (es) Derivados de heterociclil-3-sulfonilazaindol o -azaindazol como ligandos de 5-hidroxitriptamina-6
CO2017001603A2 (es) Compuestos aminopirimidinilo inhibidores de jak
AR040047A1 (es) 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6
CO5590924A2 (es) Derivados de indolilalquilamina como ligandos de 5- hidroxitriptamina-6
CO5560575A2 (es) Compuestos derivados de dihidro-pteridinonas caracterizados por ser inhibidores de especificas cinasas del ciclo celular y preparaciones farmaceuticas que los contienen
AR037489A1 (es) Quinolinas sustituidas y proceso para su preparacion
AR049399A1 (es) Difenilimidazopirimidina e -imidazol aminas como inhibidores de b-secretasa y metodo de obtencion de los mismos
AR092108A1 (es) Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn
AR040048A1 (es) Derivados de 1-(aminoalquil)-3-sulfonilindol e indazol como ligandos de la 5-hidroxitriptamina-6
AR034270A1 (es) 1-aril- o 1-alquilsulfonil-heterociclilbenzazoles como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, una composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento
AR038703A1 (es) Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
AR062499A1 (es) Derivados de n-fenil pirazol y piridil pirazoles, composiciones farmaceuticas que los contienen y usos como agentes antiagregantes plaquetarios y antitromboticos.
CR8468A (es) Derivado de n-(1,5-difenil-1h-pirazol-3-il)metil)sulfonamida con afinidad por los receptores cb1
AR036075A1 (es) Compuestos derivados de pirimidina,triazina,y,pirazina,su uso, un procedimiento para su preparacion y medicamentos que los comprenden
AR035733A1 (es) Compuestos heterociclicos terapeuticos, uso de dichos compuestos para la preparacion de medicamentos, compuestos relacionados y procedimientos para preparar estos compuestos relacionados
AR086357A1 (es) Derivados de indazol sustituidos activos como inhibidores de quinasas
CO5251381A1 (es) Derivados de adamantano, un proceso para su preparacion y composiciones farmaceuticas que los contienen
AR046200A1 (es) Derivados de pirazina y su uso farmaceutico. procesos de preparacion y composiciones farmaceuticas
AR062409A1 (es) Compuesto y composicion farmaceutica, utiles como agentes terapeuticos en el tratamiento, prevencion o mejoramiento de enfermedad o trastorno caracterizado por depositos o niveles de b-amiloide elevados o para inhibir o elucidar la enzima b-secretasa, y proceso para la preparacion del compuesto
AR034203A1 (es) Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento
AR069691A1 (es) Derivados ciclopropilamina

Legal Events

Date Code Title Description
FG Application granted
FD Application lapsed